Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Alpharadin

- PMLiVE

Bayer launches ‘Anything but Normal’ campaign highlighting women’s health issues

Over 1.5 billion women worldwide – almost one in two women – experience women’s health issues

- PMLiVE

Bayer’s Kerendia granted FDA approval for new heart failure indication

Approximately 55% of the 6.7 million adults in the US with HF have an LVEF of at least 40%

- PMLiVE

Bayer’s Vitrakvi receives full FDA approval for NTRK gene fusion-positive tumours

The US regulator first approved the TRK inhibitor in 2018 under its accelerated approval pathway

- PMLiVE

FDA grants RMAT designation to AskBio’s Parkinson’s gene therapy candidate

The progressive neurodegenerative disease affects more than ten million people worldwide

- PMLiVE

Bayer UK launches digital educational hub to improve menopause support

An estimated 13 million women in the UK are currently perimenopausal or menopausal

- PMLiVE

Bayer’s non-hormonal menopause drug shows promise in phase 3 breast cancer trial

Breast cancer patients can experience vasomotor symptoms as a result of adjuvant endocrine therapy

- PMLiVE

Bayer presents positive results for Kerendia in late-stage heart failure study

Approximately 55% of the 6.7 million heart failure patients in the US have an LVEF of at least 40%

- PMLiVE

Bayer and NextRNA Therapeutics enter oncology partnership worth $547m

The companies will advance small molecule therapeutics against a new class of targets for cancer

- PMLiVE

Bayer shares promising results for Kerendia in phase 3 heart failure study

Approximately 55% of heart failure patients have an LVEF of at least 40%

- PMLiVE

Bayer/Orion’s darolutamide combination shows promise in phase 3 prostate cancer trial

The results from the study will support regulatory applications for wider use of the drug

- PMLiVE

Bayer’s non-hormonal menopause drug elinzanetant shows promise in long-term study

Vasomotor symptoms are reported by up to 80% of women during the menopausal transition

- PMLiVE

Bayer and BridgeBio enter European partnership worth up to $310m for ATTR-CM

The rare and progressive condition affects around 500,000 people worldwide

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links